MA35274B1 - Cristal de composé hétérocyclique condensé - Google Patents

Cristal de composé hétérocyclique condensé

Info

Publication number
MA35274B1
MA35274B1 MA36695A MA36695A MA35274B1 MA 35274 B1 MA35274 B1 MA 35274B1 MA 36695 A MA36695 A MA 36695A MA 36695 A MA36695 A MA 36695A MA 35274 B1 MA35274 B1 MA 35274B1
Authority
MA
Morocco
Prior art keywords
heterocyclic compound
condensed heterocyclic
compound crystal
crystal
imidazo
Prior art date
Application number
MA36695A
Other languages
English (en)
Inventor
Katsuhiko Yamamoto
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of MA35274B1 publication Critical patent/MA35274B1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)

Abstract

La présente invention concerne un cristal de 1-éthyl-7-méthyl-3-{4-[(3- méthyl-3h-imidazo[4,5-b]pyridin-2-yl)oxy]phényl}-1,3-dihydro-2h- imidazo[4,5-b]pyridin-2-one utile en tant qu'agent prophylactique ou thérapeutique pour la schizophrénie et analogues, ledit cristal présentant un profil de diffraction des rayons x sur poudre affichant des pics caractéristiques à des distances interplanaires (d) de 13,59 plus ou moins 0,2 et de 6,76 plus ou moins 0,2 angströms dans la diffraction des rayons x sur poudre
MA36695A 2011-06-22 2014-01-20 Cristal de composé hétérocyclique condensé MA35274B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011138920 2011-06-22
PCT/JP2012/066461 WO2012176934A1 (fr) 2011-06-22 2012-06-21 Cristal de composé hétérocyclique condensé

Publications (1)

Publication Number Publication Date
MA35274B1 true MA35274B1 (fr) 2014-07-03

Family

ID=46551819

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36695A MA35274B1 (fr) 2011-06-22 2014-01-20 Cristal de composé hétérocyclique condensé

Country Status (26)

Country Link
US (1) US9512118B2 (fr)
EP (1) EP2723738B1 (fr)
JP (1) JP6025757B2 (fr)
KR (1) KR20140040777A (fr)
CN (1) CN103608348B (fr)
AR (1) AR087004A1 (fr)
AU (1) AU2012274292B2 (fr)
BR (1) BR112013032052A2 (fr)
CA (1) CA2839825C (fr)
CL (1) CL2013003632A1 (fr)
CO (1) CO6862150A2 (fr)
CR (1) CR20140033A (fr)
DO (1) DOP2013000311A (fr)
EA (1) EA026137B1 (fr)
EC (1) ECSP14013165A (fr)
GE (1) GEP20166475B (fr)
MA (1) MA35274B1 (fr)
MX (1) MX342990B (fr)
MY (1) MY163483A (fr)
PE (1) PE20141030A1 (fr)
TN (1) TN2013000510A1 (fr)
TW (1) TWI570122B (fr)
UA (1) UA112082C2 (fr)
UY (1) UY34150A (fr)
WO (1) WO2012176934A1 (fr)
ZA (1) ZA201309611B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5973990B2 (ja) * 2011-03-16 2016-08-23 武田薬品工業株式会社 縮合複素環化合物
US10851076B2 (en) 2017-08-10 2020-12-01 Pratt Bethers Method for purifying crystals using solvent vapors
US10960322B2 (en) 2018-07-02 2021-03-30 Pratt Bethers Apparatus for purifying crystals using solvent vapors
US10308626B1 (en) 2018-07-02 2019-06-04 Pratt Bethers Crystal purification in a glass or metal container
US20240052227A1 (en) * 2022-08-12 2024-02-15 Raytheon Company Water-based polymer network for transpirant cooling applications

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5597826A (en) * 1994-09-14 1997-01-28 Pfizer Inc. Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
CA2582479C (fr) * 2004-10-07 2011-07-12 Pfizer Products Inc. Derives de benzoimidazole utiles en tant qu'agents antiproliferatifs
AU2006285915B2 (en) 2005-08-30 2011-02-24 Asahi Kasei Pharma Corporation Sulfonamide compound
FI20055498A0 (fi) 2005-09-16 2005-09-16 Biotie Therapies Corp Sulfonamidijohdannaisia
US7618982B2 (en) 2005-12-19 2009-11-17 Nerviano Medical Sciences S.R.L. Heteroarylpyrrolopyridinones active as kinase inhibitors
CN101384583A (zh) * 2006-02-15 2009-03-11 塞诺菲-安万特股份有限公司 氮杂环基-取代的芳基二氢异喹啉酮、它们的制备方法和它们作为药物的用途
US20080090834A1 (en) 2006-07-06 2008-04-17 Pfizer Inc Selective azole pde10a inhibitor compounds
JP5313883B2 (ja) 2007-04-18 2013-10-09 キッセイ薬品工業株式会社 含窒素縮合環誘導体、それを含有する医薬組成物及びその医薬用途
CA2717529A1 (fr) 2008-03-11 2009-09-17 Cellzome Limited Sulfonamides en tant qu'inhibiteurs de zap-70
TW201030001A (en) 2008-11-14 2010-08-16 Amgen Inc Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors
TWI396689B (zh) 2008-11-14 2013-05-21 Amgen Inc 作為磷酸二酯酶10抑制劑之吡衍生物
WO2010126002A1 (fr) 2009-04-28 2010-11-04 塩野義製薬株式会社 Produit pharmaceutique contenant un composé sulfonamide hétérocyclique
MY165585A (en) 2010-06-24 2018-04-05 Takeda Pharmaceuticals Co Fused heterocyclic compounds as phosphodiesterases (pdes) inhibitors
US9029536B2 (en) 2010-08-04 2015-05-12 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
EP2604597B1 (fr) 2010-08-10 2017-01-04 Takeda Pharmaceutical Company Limited Composé hétérocyclique et utilisation de celui-ci comme inhibiteur de phosphodiesterase 10a
JP5973990B2 (ja) 2011-03-16 2016-08-23 武田薬品工業株式会社 縮合複素環化合物

Also Published As

Publication number Publication date
EA026137B1 (ru) 2017-03-31
GEP20166475B (en) 2016-05-10
JP2014516918A (ja) 2014-07-17
KR20140040777A (ko) 2014-04-03
EP2723738A1 (fr) 2014-04-30
ZA201309611B (en) 2014-08-27
MY163483A (en) 2017-09-15
CR20140033A (es) 2014-03-12
UA112082C2 (uk) 2016-07-25
MX342990B (es) 2016-10-20
BR112013032052A2 (pt) 2016-12-13
CN103608348A (zh) 2014-02-26
TN2013000510A1 (en) 2015-03-30
ECSP14013165A (es) 2014-02-28
PE20141030A1 (es) 2014-08-29
EP2723738B1 (fr) 2018-03-14
AU2012274292B2 (en) 2016-10-27
AR087004A1 (es) 2014-02-05
CA2839825C (fr) 2019-04-09
EA201490092A1 (ru) 2014-05-30
CO6862150A2 (es) 2014-02-10
MX2013015354A (es) 2014-02-11
UY34150A (es) 2013-01-31
WO2012176934A1 (fr) 2012-12-27
TWI570122B (zh) 2017-02-11
NZ618944A (en) 2015-08-28
US20140113932A1 (en) 2014-04-24
JP6025757B2 (ja) 2016-11-16
CL2013003632A1 (es) 2014-06-06
AU2012274292A1 (en) 2014-01-16
CA2839825A1 (fr) 2012-12-27
TW201313709A (zh) 2013-04-01
CN103608348B (zh) 2016-03-30
US9512118B2 (en) 2016-12-06
DOP2013000311A (es) 2014-02-28

Similar Documents

Publication Publication Date Title
MA35274B1 (fr) Cristal de composé hétérocyclique condensé
MA35452B1 (fr) 3-pyrimidin-4-yl-oxazolidin-2-ones comme inhibiteurs d'idh mutante
MX347562B (es) Derivados fungicidas de 3-fenil[(heterociclilmetoxi)imino]metil}-1 ,2,4-oxadiazol-5(4h)-ona sustituidos en 4.
WO2007034282A3 (fr) Composes de biphenylimidazole utilises comme antagonistes du recepteur du c3a
RS53828B1 (en) CONCLUSION OF IMIDASO [4,5-C] HINOLIN-2-ON AND ITS USE AS A DOUBLE P13 KINASE / mTOR INHIBITOR
SG195289A1 (en) Process for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
MX2019010100A (es) Compuesto de quinolona.
WO2008032157A3 (fr) Synthèse de 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
NZ605889A (en) Fused heterocyclic compounds as phosphodiesterases (pdes) inhibitors
MX2010008469A (es) Pirazolopirimidinas, procedimiento para su preparacion y su uso como medicina.
WO2008050168A8 (fr) Nouveaux dérivés sulfonamides utilisés comme antagonistes de la bradykinine
MX2013001805A (es) Derivados de 2-(arilamino)-3h-imidazo [4,5-b] piridina-6-carboxamida y su uso como inhibidores de mpges-1.
WO2014009833A3 (fr) Modulateurs de trajet de complément et leurs utilisations
WO2008104175A3 (fr) Nouveaux inhibiteurs de la phosphodiestérase
NO20080033L (no) Kinolinderivater som NK3-antagonister
MX337638B (es) Isoxazolo [5, 4-b] piridinas herbicidas.
WO2008136378A1 (fr) Nouveau dérivé de sulfonamide et son sel
ATE514698T1 (de) Tetracyclische azapyrazinoindoline als 5-ht2- liganden
WO2013106756A3 (fr) Agents antimicrobiens
HU0700756D0 (en) Process for producing pharmaceutical intermediers
MY161831A (en) New non-peptide derivatives as bradykinin b1 antagonists
MX2012012531A (es) Derivado de imidazo [1, 2-a] piridina.
WO2012035171A3 (fr) Nouveaux composés
SG166799A1 (en) Quinoline derivatives as antibacterial agents
MX2015005884A (es) Compuesto de 2-piridona.